Related Experiment Videos
[Autoimmune thrombocytopenia and pregnancy]
1Servicio de Medicina Interna, Hospital de Gineco-Obstetricia Luis Castelazo Ayala Instituto Mexicano del Seguro Social, México, D.F.
Ginecologia Y Obstetricia De Mexico
|June 1, 1995
Summary
Autoimmune thrombocytopenic purpura (PTA) affects pregnant women, posing risks to the fetus. Fetal platelet counts guide delivery decisions to prevent intracranial hemorrhage.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Neonatology
Context:
- Autoimmune thrombocytopenic purpura (PTA) is more prevalent in women of reproductive age.
- Managing pregnant patients with PTA presents unique challenges for fetal well-being.
- Maternal platelet count monitoring is straightforward, but fetal outcomes require specialized assessment.
Purpose:
- To outline the diagnostic and management strategies for fetal thrombocytopenia in pregnancies complicated by PTA.
- To highlight the importance of fetal platelet count determination before delivery.
- To establish guidelines for intervention to prevent fetal intracranial hemorrhage.
Summary:
- Percutaneous umbilical blood sampling or fetal scalp sampling can determine fetal platelet counts.
- Fetal thrombocytopenia, defined as a platelet count <50,000/mm³, necessitates specific management.
- Cesarean section is indicated for severe fetal thrombocytopenia to mitigate risks.
Impact:
- Provides a clear management pathway for clinicians caring for pregnant patients with PTA.
- Aims to improve fetal outcomes by preventing severe thrombocytopenia and associated complications.
- Contributes to reducing the incidence of fetal intracranial hemorrhage in this patient population.